Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects

NCT ID: NCT02259868

Last Updated: 2018-08-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 88 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-06-30

Brief Summary

1. To investigate the relative bioavailability (BA) of improved tablet formulation candidates to determine which formulation will be developed for use in late Phase II and Phase III clinical trials

2. To investigate the relative BA of the pediatric suspension, compared to the current 1B formulation

3. To investigate the bioequivalence (BE) of BILR 355 BS in two tablet strengths; three 25mg tablets vs. one 75 mg tablet, current 1B formulation

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A

randomized sequence of current low dose formulation (3 tablets) and high dose (1 tablet) BILR 355 BS 1B formulation, separated by 14-day washout

Group Type: EXPERIMENTAL

BILR 355 BS /1B, current low dose formulation

Intervention Type: DRUG

BILR 355 BS /1B, current high dose formulation

Intervention Type: DRUG

Ritonavir

Intervention Type: DRUG

Group B

randomized sequence of BILR 355 BS (JM) + SDS formulation low dose (2 tablets) ,BILR 355 BS (HM) + SDS formulation low dose (2 tablets), BILR 355 BS high dose 1B formulation (4 low dose tablets), separated by 14-day washout

Group Type: EXPERIMENTAL

BILR 355 BS /1B, current low dose formulation

Intervention Type: DRUG

BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention Type: DRUG

BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention Type: DRUG

Ritonavir

Intervention Type: DRUG

Group C

randomized sequence of BILR 355 BS (JM) + SDS formulation high dose (4 tablets) , BILR 355 BS (JM) + SDS formulation mid dose (3 tablets), BILR 355 BS (HM) + SDS formulation high dose (4 tablets), separated by 14-day washout

Group Type: EXPERIMENTAL

BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention Type: DRUG

BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention Type: DRUG

Ritonavir

Intervention Type: DRUG

Group D

randomized sequence of BILR 355 BS Suspension high dose, BILR 355 BS Suspension low dose, current low dose BILR 355 BS 1B formulation (3 tablets) separated by 14-day washout

Group Type: EXPERIMENTAL

BILR 355 BS /1B, current low dose formulation

Intervention Type: DRUG

BILR 355 BS - Suspension low dose

Intervention Type: DRUG

BILR 355 BS - Suspension high dose

Intervention Type: DRUG

Ritonavir

Intervention Type: DRUG

Interventions

BILR 355 BS /1B, current low dose formulation

Intervention Type: DRUG

BILR 355 BS /1B, current high dose formulation

Intervention Type: DRUG

BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention Type: DRUG

BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation

Intervention Type: DRUG

BILR 355 BS - Suspension low dose

Intervention Type: DRUG

BILR 355 BS - Suspension high dose

Intervention Type: DRUG

Ritonavir

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy HIV negative adult male volunteers

2. Age ≥18 and ≤ 60 years

3. BMI ≥18.5 and BMI ≤29.9 kg/m2

4. Ability to give signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local regulations

Exclusion Criteria

1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

2. Surgery of gastrointestinal tract (except appendectomy)

3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders

4. History of relevant orthostatic hypotension, fainting spells or blackouts

5. Chronic or relevant acute infections

6. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator

7. Intake of drugs with a long half-life (>24 hours) within at least one month prior to study drug administration and during the trial

8. Use of drugs within 10 days prior to administration or during the trial which might reasonably influence the results of the trial

9. Participation in another trial with an investigational drug within two months prior to administration or during the trial

10. Current smoker

11. Alcohol abuse (more than 60 g/day)

12. Drug abuse (positive urine test for illicit prescription or non-prescription drugs or drugs of abuse).

13. Blood donation (more than 100 mL within four weeks prior to study drug administration or during the trial)

14. Excessive physical activities (within one week prior to study drug administration or during the trial)

15. Any laboratory value outside the reference range that is of clinical relevance at screening, according to the judgment of the investigator

16. Inability to comply with dietary regimen required by the protocol

17. Infected with hepatitis B or hepatitis C viruses (defined as either being hepatitis B surface antigen, or hepatitis C antibody positive

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

1188.5

Identifier Type: -

Identifier Source: org_study_id